Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.
Cellerant's Press Releases
May 12, 2014
Cellerant Therapeutics Announces Timothy Fong as Vice President of Cellular Technologies and Jagath Reddy Junutula as Vice President of Antibody Discovery & Development
February 13, 2013
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
October 8, 2012
Cellerant Awarded SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia